Visuoperceptual and visuospatial alterations in neurodegenerative diseases: a narrative review
- 1Corresponding author at: Clínica Neurobase, Calle La Luna nº 21, local, 23009 Jaén, Spain.
Abstract
Introduction: There is growing evidence suggesting that alterations in higher-level visual processing are a frequent and clinically relevant symptom in such neurodegenerative diseases as Alzheimer’s disease, multiple sclerosis, and Lewy body dementia. Some 70% of patients with Lewy body dementia are estimated to present visuoperceptual deficits during the course of the disease. Development: This text summarises the most common visuoperceptual and visuospatial alterations associated with neurodegenerative diseases commonly seen in neurology and neuropsychology practice, highlighting some of the most widely used neuropsychological tests for their detection. Moreover, it emphasises the relevance of these alterations not only for the initial and differential diagnosis of such conditions but also for predicting patients' prognosis and clinical progression across the different stages of the disease. Conclusions: Future research should focus on developing new cognitive assessment tools that integrate current advances in the understanding of higher-level visual processing and neurodegenerative diseases. Early, accurate identification of visuoperceptual and visuospatial deficits is not only essential for early and differential diagnosis but also can provide valuable information about disease progression and help guide more personalised therapeutic interventions.
Related
- Modeling Strategies for Neurodegenerative Diseases: In Vitro, In Vivo and In Silico Frameworks
- Editorial: Glucose metabolism in brain and neurodegenerative diseases: multifactorial effects
- Brain-computer interfaces for neurodegenerative diseases: A comprehensive review of closed-loop systems from diagnosis to neural rehabilitation
- Diagnosing Neurodegenerative Diseases by Label-Free 3-D Imaging of Intestinal Samples
- Biological age measured by DNA methylation clocks and neurodegenerative diseases: A systematic review and meta-analysis
BibTeX
@article{martineznogueras2026visuoperceptual,
title = {{Visuoperceptual and visuospatial alterations in neurodegenerative diseases: a narrative review}},
author = {Á.L. Martínez-Nogueras},
journal = {Neurology Perspectives},
year = {2026},
month = oct,
doi = {10.1016/j.neurop.2026.100231},
url = {https://doi.org/10.1016/j.neurop.2026.100231},
note = {CC BY},
}
RIS
TY - JOUR
TI - Visuoperceptual and visuospatial alterations in neurodegenerative diseases: a narrative review
AU - Á.L. Martínez-Nogueras
PY - 2026
DA - 2026/10/24
JO - Neurology Perspectives
DO - 10.1016/j.neurop.2026.100231
UR - https://doi.org/10.1016/j.neurop.2026.100231
AB - Introduction: There is growing evidence suggesting that alterations in higher-level visual processing are a frequent and clinically relevant symptom in such neurodegenerative diseases as Alzheimer’s disease, multiple sclerosis, and Lewy body dementia. Some 70% of patients with Lewy body dementia are estimated to present visuoperceptual deficits during the course of the disease. Development: This text summarises the most common visuoperceptual and visuospatial alterations associated with neurodegenerative diseases commonly seen in neurology and neuropsychology practice, highlighting some of the most widely used neuropsychological tests for their detection. Moreover, it emphasises the relevance of these alterations not only for the initial and differential diagnosis of such conditions but also for predicting patients' prognosis and clinical progression across the different stages of the disease. Conclusions: Future research should focus on developing new cognitive assessment tools that integrate current advances in the understanding of higher-level visual processing and neurodegenerative diseases. Early, accurate identification of visuoperceptual and visuospatial deficits is not only essential for early and differential diagnosis but also can provide valuable information about disease progression and help guide more personalised therapeutic interventions.
SN - 2667-0496
ER -